MedTrace Logo

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

NCT03081715 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-06-12

No results posted yet for this study

Summary

This study will evaluate the safety of PD-1 knockout engineered T cells in treating advanced esophageal cancer. Blood or tissue samples will also be collected for research purposes.

Conditions

  • Esophageal Cancer

Interventions

OTHER

PD-1 Knockout T Cells

Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9

Sponsors & Collaborators

  • Anhui Kedgene Biotechnology Co.,Ltd

    collaborator UNKNOWN

  • Hangzhou Cancer Hospital

    lead OTHER

Principal Investigators

  • shixiu wu, Professor · Hangzhou Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-14
Primary Completion
2018-01-23
Completion
2018-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03081715 on ClinicalTrials.gov